Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 18 2024
0mins
Should l Buy ?
Source: newsfilter
- Calliditas Therapeutics Presentation: Calliditas presented additional data analyses from the Phase 3 NeflgArd trial of Nefecon for IgA nephropathy at the ISN World Congress of Nephrology.
- Poster Presentation Analyses: Detailed findings included improved kidney benefits with Nefecon treatment, sustained eGFR improvement, and support in reaching RaDaR treatment targets.
- eGFR Decline Results: Nefecon showed a reduction in UPCR, lower risk of eGFR decline or kidney failure, and delayed time to such events compared to placebo.
- Quality of Life Analysis: SF-36 results showed consistent quality of life between Nefecon and placebo groups over 2 years, supporting the benefit/risk profile of Nefecon.
- Treatment Response Across Populations: Nefecon demonstrated favorable responses in Asian and White patient populations, showing efficacy, tolerability, and reduced microhematuria rates across racial and ethnic groups.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
